SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF
FOREIGN ISSUER
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For
the month of November 2006
Commission
File Number 000-51122
pSivida
Limited
(Translation
of registrant’s name into English)
Level
12 BGC Centre
28
The Esplanade
Perth
WA 6000
Australia
(Address
of principal executive offices)
(Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F).
Form
20-F
ý Form
40-F o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7):
Indicate
by check mark whether the registrant by furnishing the information contained
in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
o No
ý
If
"Yes"
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82- ___.
The
document attached as Exhibit 99.1 to this Report on Form 6-K is hereby
incorporated by reference herein and into the following registration statements:
(i) the Registrant's Registration Statement on Form F-3, Registration
No. 333-132776; (ii) the Registrant's Registration Statement on
Form F-3, Registration No. 333-132777; and (iii) the Registrant's
Registration Statement on Form F-3, Registration
No. 333-135428.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant,
pSivida Limited, has duly caused this report to be signed on its behalf by
the
undersigned, thereunto duly authorized.
Date:
November 20, 2006
| PSIVIDA LIMITED | ||
| |
|
|
| By: | /s/ Aaron Finlay | |
|
Aaron Finlay |
||
| Company Secretary | ||
EXHIBIT
INDEX
|
EXHIBIT
99.1:
|
Transdermal
Drug Delivery Program - Collaboration with global electronics
company
|
| ASX/Media RELEASE |
20
November
2006
|
Transdermal
Drug Delivery Program
Collaboration
with global electronics company
Boston,
MA. and Perth, Australia - Global bio-nanotech company pSivida Limited (ASX:PSD,
NASDAQ:PSDV, Xetra:PSI) is
pleased to announce that it has entered into a collaboration with a global
electronics and technology company
to evaluate its BioSilicon™
technology (nano-structured silicon) for the development of transdermal drug
delivery systems. The collaboration combines the expertise of the
undisclosed multinational company in the development and production of
microelectromechanical systems (MEMS) with pSivida’s core competency in drug
delivery.
During
the twelve month program, the parties will jointly develop and evaluate a range
of biodegradable porous silicon structures, including microneedles, for the
controlled release of drugs via the transdermal route.
Transdermal
delivery of drugs avoids the use of invasive needle-based
injection with its associated pain and discomfort. There is significant interest
in transdermal delivery systems for the delivery of a range of therapeutic
entities, from conventional small drug molecules to larger peptides,
proteins
and vaccines. According to Frost & Sullivan, the United States transdermal
drug delivery market could reach US$4.5 billion by 2012.
“We
are
very pleased to have entered into this joint program with a partner who brings
considerable materials experience and global industrial presence to complement
our drug delivery expertise,” said Dr Roger Brimblecombe, Chairman and CEO of
pSivida Limited.
-ENDS-
Released
by:
|
pSivida
Limited
Brian
Leedman
Director
of Investor Relations
pSivida
Limited
Tel:
+ 61 8 9226 5099
brianl@psivida.com
|
US
Public Relations
Beverly
Jedynak
President
Martin
E. Janis & Company, Inc
Tel:
+1 (312) 943 1100 ext. 12
bjedynak@janispr.com
|
European
Public Relations
Accent
Marketing limited
Eva
Reuter
Tel:
+49 (254) 393 0740
e.reuter@e-reuter-ir.com
|
NOTES
TO EDITORS:
pSivida
is a global bio-nanotech company committed to the biomedical sector and the
development of drug delivery products. Retisert™ is FDA approved for the
treatment of uveitis. Vitrasert® is FDA approved for the treatment of
AIDS-related CMV Retinitis. Bausch & Lomb own the trademarks Vitrasert® and
Retisert™. pSivida has licensed the technologies underlying both of these
products to Bausch & Lomb. The technology underlying Medidur™, a treatment
for diabetic macular edema, is licensed to Alimera Sciences and is in Phase
III
clinical trials.
pSivida
owns the rights to develop and commercialise a modified form of silicon
(porosified or nano-structured silicon) known as BioSilicon™, which has
applications in drug delivery, wound healing, orthopaedics, and tissue
engineering. pSivida’s subsidiary, AION Diagnostics Limited is developing
diagnostic products and the subsidiary pSiNutria is developing food technology
products both using BioSilicon™.
pSivida’s
intellectual property portfolio consists of 76 patent families, 95 granted
patents including patents accepted for issuance and over 300 patent
applications.
pSivida
conducts its operations from offices and facilities near Boston in the United
States, Malvern in the United Kingdom, Perth in Australia and Singapore.
pSivida
is listed on NASDAQ (PSDV),
the
Australian Stock Exchange (PSD)
and on
the Frankfurt Stock Exchange on the XETRA system (German Symbol:
PSI. Securities Code (WKN) 358705).
pSivida is a founding member of the NASDAQ Health Care Index and the Merrill
Lynch Nanotechnology Index.
This
document contains forward-looking statements that involve risks and
uncertainties including with respect to our potential development of transdermal
drug delivery products and the size of the potential market for transdermal
drug
delivery products generally; and potential products, applications and regulatory
approvals. Although we believe that the expectations reflected in such
forward-looking statements are reasonable at this time, we can give no assurance
that such expectations will prove to be correct. Given these uncertainties,
readers are cautioned not to place undue reliance on such forward-looking
statements. Actual results could differ materially from those anticipated in
these forward-looking statements due to many important factors including:
failure of the company and its partner to successfully develop transdermal
drug
delivery products; failure of there to continue to be synergies between pSivida
and Alimera Sciences; failure of Medidur for DME to be an innovative treatment
for DME; failure of the results of the Retisert™ for DME trial to be a good
indicator of the results of pSivida’s ongoing Phase III Medidur™ for DME
trial; failure of the Medidur™ trials in DME to show a very similar improvement
in visual acuity and diabetic retinopathy severity score as Retisert™ for DME;
failure of Medidur™ to release fluocinolone acetonide at the same rate as
Retisert™; our inability to recruit patients for the Phase III Medidur™ for
DME trial;; our (and our subsidiaries’) failure to develop proposed products,
including without limitation, in the drug delivery, wound healing, orthopaedics,
and tissue engineering, diagnostics and food technology fields; and failure
to
develop applications for BioSilicon™ due to regulatory, scientific or other
issues;. Other reasons are contained in cautionary statements in the Annual
Report on Form 20-F filed with the U.S. Securities and Exchange Commission,
including, without limitation, under Item 3.D, "Risk Factors" therein. We do
not
undertake to update any oral or written forward-looking statements that may
be
made by or on behalf of pSivida.